课题基金 / 基金详情

Papillomavirus E2 as a cervical/anal cancer drug target

Papillomavirus E2 as a cervical/anal cancer drug target
乳头瘤病毒 E2 作为宫颈癌/肛门癌的药物靶点
批准号:
6915013
负责人:
JANET L BRANDSMA
金额:
$24.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2007-08-31

项目摘要

项目成果

JANET L BRANDSMA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):尽管引入了有效的抗逆转录病毒治疗,但艾滋病患者的宫颈癌和肛门癌的发病率仍然很高。由于这些恶性肿瘤及其前体是由人乳头瘤病毒(HPV)引起的,因此艾滋病患者的治疗最大希望在于开发抗HPV药物。 HPVE2蛋白是药物开发的合理靶点,因为它对乳头瘤病毒复制至关重要。此外,它还激活病毒E6/E7癌基因的转录,导致细胞增殖。然而,E2也阻止了不受控制的E6/E7表达,使E2功能的丧失成为HPV相关致癌的关键步骤,并引发了人们对开发抗E2药物的智慧的严重担忧。也有体外研究表明,E2的过度表达可能具有治疗作用。对治疗干预目标最明确的评估是通过动物研究。虽然在体外对E2蛋白的作用进行了深入的研究,但在哺乳动物宿主中所做的工作很少。这项拟议的研究旨在通过有条件的转基因来确定在乳头状瘤病毒诱导的疾病动物模型中调节E2活性的效果。由于在实验环境中唯一会导致乳头状瘤和癌症的乳头状瘤病毒基因组是棉尾兔乳头状瘤病毒(CRPV),因此将使用CRPV-兔模型。 其具体目标是创建包含CRPV全长基因组和四环素调控的E2转基因的载体。含有E2显性负性转基因的载体将被用来确定E2失活对乳头状瘤生长、组织病理学、CRPVDNA拷贝数、E6/E7转录、细胞增殖和细胞凋亡的影响。含有条件野生型CRPVE2转基因的载体将被用来确定E2过度表达的影响。
英文摘要
DESCRIPTION (provided by applicant): The incidence of cervical and anal cancers in AIDS patients has remained substantial despite the introduction of potent antiretroviral therapy. Because these malignancies and their precursors are caused by human papillomavirus (HPV), the best hope for treatment in AIDS patients lies with the development of anti-HPV drugs. The HPV E2 protein is a logical target for drug development because it is critical for papillomavirus replication. In addition, it activates transcription of the viral E6/E7 oncogenes that cause cellular proliferation. However, E2 also prevents uncontrolled E6/E7 expression, making the loss of E2 function a critical step for HPV-associated carcinogenesis and raising serious concern over the wisdom of developing anti-E2 drugs. There also are in vitro studies indicating that E2 overexpression may be therapeutic. The most definitive assessment of a target for therapeutic intervention is through animal studies. While the actions of the E2 protein are being intensively studied in vitro, little work is being done in mammalian hosts. The proposed research aims to determine the effects of modulating, by conditional transgenesis, E2 activity in an animal model of papillomavirus-induced disease. Because the only papillomavirus genome that induces papillomas and carcinomas in experimental settings is the cottontail rabbit papillomavirus (CRPV), the CRPV-rabbit model will be used. The specific aims are to create vectors containing a full-length CRPV genome and a tetracycline-regulated E2 transgene. Vectors containing an E2 dominant-negative transgene will be used to determine the effects of E2 inactivation on papilloma growth, histopathology, CRPV DNA copy number, E6/E7 transcription, cellular proliferation and apoptosis. Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
  • 批准号:
    7530393
  • 项目类别:
  • 资助金额:
    $18.62万
  • 财政年份:
    2008
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
Langerhans cell-mediated immune modulation of HPV8 expression and tumorgenesis
  • 批准号:
    7624197
  • 项目类别:
  • 资助金额:
    $22.34万
  • 财政年份:
    2008
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
Papillomavirus E2 as a cervical/anal cancer drug target
  • 批准号:
    6844396
  • 项目类别:
  • 资助金额:
    $23.39万
  • 财政年份:
    2004
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
VSV-based Therapeutic Papilloma Vaccine
  • 批准号:
    6761813
  • 项目类别:
  • 资助金额:
    $32.74万
  • 财政年份:
    2003
  • 负责人:
    JANET L BRANDSMA
  • 依托单位:
海外基金